CLSD - Triple Bottom. Huge Analyst Prediction Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Average Recommendation: OVERWEIGHT
Average Target Price: 5.50
SHORT INTEREST
2.26M 07/15/19
P/E Current
-0.48
P/E Ratio (with extraordinary items)
-0.72
